cstu
Footballguy
The costs of innovation and negotiation
Miller got a round of applause for suggesting that the rest of the world take up some of the burden that the U.S. currently shoulders for high drug prices. But it raises the question: If prices in other countries were to come more in line with those in the U.S., what would happen? Would prices here drop, or would everyone simply pay more?
Reilly agreed that other countries should pay more for drugs: "Unfortunately, we're the only country in the world that still values some of the innovation that is coming to market," she said.
Certner had a different take:
"I would say we're the only country in the world that doesn't use the marketing power the rest of the world does" to bring prices down, he said.
The elephant on the sidelines is the U.S. government itself, which would have significant negotiating power -- if it were allowed to negotiate, which it's not. This part of the issue is one of the wonkiest subjects to have percolated into the 2016 presidential race, with Hillary Clinton and Bernie Sanders both promising to combat high drug prices by allowing Medicare to negotiate. Among Republicans, using the government's bargaining power against the drug industry is a non-starter -- with the notable exception of Donald Trump, who perhaps can't resist the chance to use the government's power to wheel and deal on a truly grandiose scale. Trump has claimed that allowing Medicare to negotiate could save $300 billion, but that is almost certainly a huge overestimate since, in 2015, the total Medicare prescription drug spending for its part D benefit was projected to be $85 billion.
Miller, who is very familiar with the business of negotiating drug prices, said that the ability to negotiate itself would have only a limited impact -- unless Medicare could also exclude some medications from its formulary of covered drugs, something that it doesn't currently do. Playing hardball by refusing to cover other pricy hepatitis C drugs was how Miller's company was able to negotiate a discount on the drugs that allowed Express Scripts to save $1 billion in 2015. Negotiating without being able to say "no" to any particular drug is a weak bargaining position -- and possibly not a solution that any of the players on the stage would readily embrace.
Last edited by a moderator: